Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
SC TC EN
SC TC EN
Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
汝佳宁®

Product List
Product Overview
Guideline Recommendations
Academic Publications
汝佳宁®

Lerociclib Hydrochloride Tablets

High Selectivity
High CDK4 selectivity
High Selectivity
High Penetration
High tumor tissue penetration
High Penetration
High Benefit
Low HR compared with other CDK4/6 inhibitors
High Benefit
Low Discontinuation
Low rate of treatment discontinuation due to adverse events (AEs)
Low Discontinuation
The following product information is intended for use by healthcare professionals only.
The following product may not have been approved and/or licensed for marketing in all countries where this website is accessible.
汝佳宁®
Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Product information stated by NMPA in Approved Drug Catalog of China.
【Name】

Generic Name：Lerociclib Hydrochloride Tablets

Brand Name：汝佳宁® 

Chinese Pinyin：Yansuan Lailuoxili Pian
【Ingredients】

Active Ingredient: Lerociclib Hydrochloride

Excipients:  Microcrystalline Cellulose (MCC), Croscarmellose Sodium (CCS-Na), Hydroxypropyl Methylcellulose (HPMC), Magnesium Stearate (MgSt), Film-Coating Premix (Enteric-Soluble Type).

【Appearance】

Film-coated tablet, which appears off-white to yellow,after removing the coating.

【Indications】

·in combination with an aromatase inhibitor as initial endocrinebased therapy for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

·in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.

【Specification】
50 mg (calculated as C26H34N8O）
For detailed product information, please download the full package insert (PDF).


Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Guideline Recommendations
CHINA ANTI CANCER ASSOCIATION & Oncology Society of Chinese Medical Association: Guidelines and norms for the diagnosis and treatment of breast cancer（2025）

First-line treatment recommendation for patients with HR+/HER2- advanced breast cancer: CDK4/6 inhibitor combined with aromatase inhibitor (AI)

Second-line and later-line regimens for patients with HR+/HER2- advanced breast cancer: For patients who have not previously received a CDK4/6 inhibitor, CDK4/6 inhibitor combined with AI or fulvestrant is recommended.

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines（2025）

AI + CDK4/6 inhibitor is a Category I recommended regimen (Level IA) for HR+/HER2- advanced breast cancer patients without prior endocrine therapy.

CDK4/6 inhibitor + fulvestrant is a Category I recommended regimen (Level IA) for HR+/HER2- advanced breast cancer patients who experienced disease progression after first-line of AI therapy.

Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China（2024）

First-line Treatment for HR+/HER2- Advanced Breast Cancer: CDK4/6 Inhibitor Combined with Endocrine Therapy is Recommended.

Second-line and Later-line Treatment for HR+/HER2- Advanced Breast Cancer: Fulvestrant + CDK4/6 Inhibitor is Preferred for Patients Naive to CDK4/6 Inhibitors.

Academic Publications

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

Published in：2025 Nature Communications
Year：2024
Read More

LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer.

Published in：2024ASCO
Year：2024
Read More

LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.



Published in：2023 ASCO
Year：2023
Read More
Technology Platforms
Product Center
About Us
Full Value Chain
News
Investor Relations
Contact Us

沪ICP备2021007464号

Copyright © 2025 design by EDDING

药监局备案号: (沪) -非经营性-2021-0038